Clinical and Translational Oncology

, Volume 12, Issue 10, pp 652–661

Myelodysplastic syndromes: an update on molecular pathology

Educational Series Molecular and Cellular Biology of Cancer

Abstract

The myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders characterised by impaired peripheral blood cell production due to bone marrow dysplasia affecting one or more of the major myeloid cell lines. MDS are one of five major categories of myeloid neoplasms according to the World Health Organization (WHO) classification system for haematological cancers. Given their cytological and cytogenetic heterogeneity, these diseases probably constitute a group of molecularly distinct entities with variable degrees of ineffective haematopoiesis and susceptibility to leukaemic transformation. Recent studies provide some insights into the physiopathology of MDS. In the early stages, one mechanism contributing to hypercellular marrow and peripheral blood cytopenia is a significant increase in programmed cell death (apoptosis) in haematopoietic cells. Furthermore, altered responses in relation to cytokines, the immune system and bone marrow stroma also contribute to the disease phenotype. Deletions of chromosome 5q31–q32 are the most common recurring cytogenetic abnormalities detected in MDS. The 5q- syndrome is a new entity recognised in the WHO classification since 2001 and is associated with a good prognosis. Haploinsufficiency of multiple genes mapping to the common deleted region at 5q31–32 may contribute to the pathogenesis of 5q- syndrome and other MDS with 5q- deletion. Many studies have demonstrated that altered DNA methylation and histone acetylation can alter gene transcription. Abnormal methylation of transcription promoter sites is universal in patients with MDS, and the number of involved loci is increased in high-risk disease and secondary leukaemias. A better understanding of the pathogenesis of MDS can contribute to the development of new treatments such as hypomethylating drugs, immunomodulatory agents such as lenalidomide, and immunosuppressive drugs aimed at reversing the specific alteration that results in improvement in patients with MDS.

Keywords

Myelodysplastic syndromes Molecular pathogenesis 5q- syndrome and haploinsufficiency Epigenetic changes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett JM, Catovsky D, Daniel MT et al (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  2. 2.
    Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292–2302CrossRefPubMedGoogle Scholar
  3. 3.
    Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 5:937–951CrossRefGoogle Scholar
  4. 4.
    Rollinson DE, Howlader N, Smith MT et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112:45–52CrossRefGoogle Scholar
  5. 5.
    Strom SS, Gu Y, Gruschkus SK et al (2005) Risk factors of myelodysplastic syndromes: a case control study. Leukemia 19:1912–1918CrossRefPubMedGoogle Scholar
  6. 6.
    Owen C, Barnett M, Fitzgibbon J (2008) Familial myelodysplasia and acute myeloid leukemia: a review. Br J Haematol 140:123–132CrossRefPubMedGoogle Scholar
  7. 7.
    Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C (2002) Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99:1909–1912CrossRefPubMedGoogle Scholar
  8. 8.
    Mufti GJ (1992) Chromosomal deletions in the myelodysplastic syndrome. Leuk Res 16:35–41CrossRefPubMedGoogle Scholar
  9. 9.
    Rigolin GM, Bigoni R, Milani R et al (2001) Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype. Leukemia 15:1841–1847PubMedGoogle Scholar
  10. 10.
    Fenaux P (2001) Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Haematol 12:1841–1847Google Scholar
  11. 11.
    Mhawech P, Saleem A (2001) Myelodysplastic syndrome review of the cytogenetic and molecular data. Crit Rev Oncol Hematol 73:429–437Google Scholar
  12. 12.
    Bennet JM, Komorokj R, Kouldes PA (2004) The myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Niederhuber JE et al (eds) Clinical oncology, 3rd edn. Elsevier, Philadelphia, PA, pp 2849–2882Google Scholar
  13. 13.
    Shali W, Helias C, Foher C et al (2006) Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias conventional cytogenetics FISH and multiplex FISH. Cancer Genet Cytogenet 168: 133–145CrossRefPubMedGoogle Scholar
  14. 14.
    Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088PubMedGoogle Scholar
  15. 15.
    Macovati L, Germing U, Kuendgen A et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510CrossRefGoogle Scholar
  16. 16.
    Raza A, Gezer S, Mundle S et al (1997) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 89:1690–1700Google Scholar
  17. 17.
    Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A (1997) Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 21:415–425CrossRefPubMedGoogle Scholar
  18. 18.
    Parker JE, Fishlock KL, Mijovic A et al (1998) ’Low-risk’ myelodysplastic syndromes is associated with excessive apoptosis and increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 103:1075–1082CrossRefPubMedGoogle Scholar
  19. 19.
    Parker JE, Mufti GJ, Rasool F et al (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96:3932–3938PubMedGoogle Scholar
  20. 20.
    Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E et al (1999) Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in ‘good’ versus ‘poor’ prognosis patients and correlation with apoptosis-related genes. Leukemia 13:1554–156CrossRefPubMedGoogle Scholar
  21. 21.
    Greenberg PL, Sun Z, Miller KB et al (2009) Treatment of myelodysplastic syndromes patients with erythropoietin with or with-out granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood 114:2393–2400CrossRefPubMedGoogle Scholar
  22. 22.
    Economopoulou C, Pappa V, Papageorgiou S et al (2010) Cell cycle and apoptosis regulatory gene expression in bone marrow of patients with de novo myelodysplastic syndromes. Ann Hematol 89:349–358CrossRefPubMedGoogle Scholar
  23. 23.
    Economopoulou C, Pappa V, Kontsioti F et al (2008) Analysis of apoptosis regulatory genes expression in the bone marrow of adult de novo myelodysplastic syndromes. Leukemia Res 32:61–69CrossRefGoogle Scholar
  24. 24.
    Gersuk GM, Lee JE, Beckham CA et al (1996) Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 88:1122–1123PubMedGoogle Scholar
  25. 25.
    Benesch M, Platzbecker U, Ward J et al (2003) Expression of FLIPlong and FLIPshort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis. Leukemia 17:2460–2466CrossRefPubMedGoogle Scholar
  26. 26.
    De Melo Campos P, Traina F, da Silva Santos Duarte A et al (2007) Reduced expression of FLIP SHORT in bone marrow of low risk myelodysplastic syndrome. Leuk Res 31:853–857CrossRefPubMedGoogle Scholar
  27. 27.
    Schmidt-Mende J, Tehranchi R, Forsblom AM et al (2001) Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 15:742–751CrossRefPubMedGoogle Scholar
  28. 28.
    Kerbauy DB, Deeg HJ (2007) Apoptosis and antiapoptotic mechanisms in the progression of MDS. Exp Hematol 35:1739–1746CrossRefPubMedGoogle Scholar
  29. 29.
    Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309–1312CrossRefPubMedGoogle Scholar
  30. 30.
    Hengartner MO (2000) The biochemistry of apoptosis. Nature 407:770–776CrossRefPubMedGoogle Scholar
  31. 31.
    Tehranchi R, Fadeel B, Forsblom A et al (2003) Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria- dependent apoptosis of myelodysplastic syndrome. Blood 101:1080–1086CrossRefPubMedGoogle Scholar
  32. 32.
    Tehranchi R, Fadeel B, Schmidt-Mende J et al (2005) Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 11:6291–6299CrossRefPubMedGoogle Scholar
  33. 33.
    Fadeel B, Orrenius S, Zhivotovsky B (2000) The most unkindest cut of all: on the multiple roles of mammalian caspases. Leukemia 14:1514–1525CrossRefPubMedGoogle Scholar
  34. 34.
    Braun T, Carvalho G, Coquelle A et al (2006) NF-KB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107:1156–1165CrossRefPubMedGoogle Scholar
  35. 35.
    Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factor. Oncogene 18:6910–6924CrossRefPubMedGoogle Scholar
  36. 36.
    Kerbaury DB, Lesnikov V, Abbasi N et al (2005) NF-κB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes. Blood 106:3917–3925CrossRefGoogle Scholar
  37. 37.
    Bernasconi P (2008) Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review. Br J Haematol 142:695–708CrossRefPubMedGoogle Scholar
  38. 38.
    Stirewalt DL, Mhyre AJ, Marcondes M et al (2008) Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? Br J Haematol 140:444–453CrossRefPubMedGoogle Scholar
  39. 39.
    Marcondes MA, Mhyre AJ, Stirewalt DL et al (2008) Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A 105:2865–2870CrossRefPubMedGoogle Scholar
  40. 40.
    Sloand EM, Wu CO, Greemberg P et al (2008) Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26:2505–2511CrossRefPubMedGoogle Scholar
  41. 41.
    Fozza C, Contini S, Galleu A et al (2009) Patients with myelodysplastic syndromes display several T-cell expansions which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 37:947–955CrossRefPubMedGoogle Scholar
  42. 42.
    Sloand EM, Rezvani K (2008) The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 45:39–48CrossRefPubMedGoogle Scholar
  43. 43.
    Sloand EM, Mainwaring L, Fuhrer M et al (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106:841–851CrossRefPubMedGoogle Scholar
  44. 44.
    Kotsiannidis I, Bouchliou I, Nakou E et al (2009) Kinetics, function and bone marrow trafficking of CD4+, CD25+ FOXP3+ regulatory T cells in myelodysplastic syndromes. Leukemia 23:510–518CrossRefGoogle Scholar
  45. 45.
    Sole F, Espinet B, Sanz GF et al (2000) Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica. Br J Haematol 108:346–356CrossRefPubMedGoogle Scholar
  46. 46.
    Ebert BL (2009) Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 23:1252–1256CrossRefPubMedGoogle Scholar
  47. 47.
    Pedersen B (1998) 5q(-) survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Leuk Lymphoma 31:325–334PubMedGoogle Scholar
  48. 48.
    Lai F, Godley LA, Joslin J et al (2001) Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid disease with a del (5q). Genomics 71:235–245CrossRefPubMedGoogle Scholar
  49. 49.
    Boultwood J, Pellagatti A, Cattan H et al (2007) Gene expression profiling of CD34+ cells in pa tients with the 5q- syndrome. Br J Haematol 139: 578–589CrossRefPubMedGoogle Scholar
  50. 50.
    Shannon KM, Le Beau MM (2008) Cancer: hay in a hay-stack. Nature 451:252–253CrossRefPubMedGoogle Scholar
  51. 51.
    Ebert BL, Pretz J, Bosco J et al (2008) Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451:335–339CrossRefPubMedGoogle Scholar
  52. 52.
    Pellagatti A, Jädersten M, Forsblom AM et al (2007) Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 104:11406–11411CrossRefPubMedGoogle Scholar
  53. 53.
    Joslin JM, Fernald AA, Tennant TR et al (2007) Haploinsufficiency of EGR1, a candidate gene in the del (5q), leads to the development of myeloid disorders. Blood 110:719–726CrossRefPubMedGoogle Scholar
  54. 54.
    Liu TX, Becker MW, Jelinek J et al (2007) Chromosome 5q deletion and epigenetic suppression of gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13:78–83CrossRefPubMedGoogle Scholar
  55. 55.
    Wei S, Chen X, Rocha K et al (2009) A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomida. Proc Natl Acad Sci U S A 106:12974–12979CrossRefPubMedGoogle Scholar
  56. 56.
    Wang J, Fernald AA, Anastasi J et al (2010) Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood 115:3481–3488CrossRefPubMedGoogle Scholar
  57. 57.
    Grisendi S, Bernardi R, Rossi M et al (2005) Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437:147–153CrossRefPubMedGoogle Scholar
  58. 58.
    Dana SL, Chang S, Wasmunth JJ (1985) Synthesis and incorporation of human ribosomal protein S14 into functional ribosomes in human-Chinese hamster cell hybrids containing human chromosome 5: human RPS14 gene is the structural gene for ribosomal protein S14. Somat Cell Mol Genet 11:625–631CrossRefPubMedGoogle Scholar
  59. 59.
    Pellagatti A, Hellström-Lindberg E, Giagounidis A et al (2008) Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 142:57–64CrossRefPubMedGoogle Scholar
  60. 60.
    Mohamendali A, Mufti GL (2008) Van-den Berghe’s 5q- syndrome in 2008. Br J Haematol 144: 157–168CrossRefGoogle Scholar
  61. 61.
    Narla A, Ebert BL (2010) Ribosomopathies: human disorders of ribosome dysfunction. Blood 115:3196–3205CrossRefPubMedGoogle Scholar
  62. 62.
    Yiu GK, Chan WY, Ng SW et al (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159:609–622PubMedGoogle Scholar
  63. 63.
    DiMartino JF, Lacayo NJ, Varadi M et al (2006) Low or absent SPARC expression in acute myeloid leukaemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20:426–432CrossRefPubMedGoogle Scholar
  64. 64.
    List A, Dewald G, Bennett J et al (2006) Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355: 1456–1465CrossRefPubMedGoogle Scholar
  65. 65.
    Min IM, Pietramaggiori G, Kim FS et al (2008) The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. Cell Stem Cell 2:380–391CrossRefPubMedGoogle Scholar
  66. 66.
    Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1:55–67CrossRefPubMedGoogle Scholar
  67. 67.
    Falini B, Mecucci C, Tiacci E, et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with normal karyotipe. N Engl J Med 352:254–266CrossRefPubMedGoogle Scholar
  68. 68.
    Sportoletti P, Grisendi S, Majid SM et al (2008) Nmp1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 111:3859–3862CrossRefPubMedGoogle Scholar
  69. 69.
    Robertson KD, Woffe AP (2000) DNA methylation in health and disease. Nat Rev Genet 1:11–19CrossRefPubMedGoogle Scholar
  70. 70.
    Rice JC, Allis CD (2001) Code of silence. Nature 414:258–261CrossRefPubMedGoogle Scholar
  71. 71.
    Toyota M, Ahuja N, Ohe-Toyota M et al (1999) GpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96:8681–8686CrossRefPubMedGoogle Scholar
  72. 72.
    Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683–692CrossRefPubMedGoogle Scholar
  73. 73.
    Agalioti T, Cheb G, Thanos D (2002) Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381–392CrossRefPubMedGoogle Scholar
  74. 74.
    Boumber YA, Kondo Y, Chen X (2007) RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 67:1997–2005CrossRefPubMedGoogle Scholar
  75. 75.
    Quesned B, Guillerm G, Verseecque R et al (1988) Methylation of the P15NK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990Google Scholar
  76. 76.
    Tien HF, Tang JL, Tsay W (2001) Methylation of the p15NK4b gene in myelodysplastic syndrome it can be detected early at diagnosis or during disease progression and is highly associated with leukemic transformation. Br J Haematol 112:148–154CrossRefPubMedGoogle Scholar
  77. 77.
    Jiang Y, Dunbar A, Gondek LP et al (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–1325CrossRefPubMedGoogle Scholar
  78. 78.
    Hofmann WK, Lübert M, Hoelzer D, Koeffer P (2004) Myelodysplastic syndromes. Hematol J 5:1–8CrossRefPubMedGoogle Scholar
  79. 79.
    Deguchi K, Gilliland DG (2002) Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 16:740–744CrossRefPubMedGoogle Scholar
  80. 80.
    Pellagatti A, Cazzola M, Giagounidis A et al (2010) Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24:756–765CrossRefPubMedGoogle Scholar
  81. 81.
    Olney JH, Le Beau MM (2001) The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 14:479–495CrossRefPubMedGoogle Scholar
  82. 82.
    Epling-Burnette PK, List AF (2009) Advancements in the molecular pathogenesis of myelodysplastic syndrome. Curr Opin Hematol 16:70–76CrossRefPubMedGoogle Scholar
  83. 83.
    Mohamedali A, Mufti GJ (2008) Van-den Berghe’s 5q- syndrome in 2008. Br J Haematol 144: 157–168CrossRefPubMedGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  1. 1.Hematology and Oncology ServiceValencia University Clinic HospitalValenciaSpain

Personalised recommendations